The influence of mutant lactobacilli on serum creatinine and urea nitrogen concentrations and renal pathology in 5/6 nephrectomized rats

Wang, Fang; Jiang, Yao; Liu, Fang

doi:10.1080/0886022x.2016.1227617

Cited by 7 publications

(4 citation statements)

References 19 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparison of biochemical parameters among the mice in the PTX-SLN@CUD acute toxicity group compared to the control group showed that one mouse had an LDH value that was slightly below the reference range, while the CREA index of another mouse was slightly lower than the reference range without any clinical guiding significance (Table 5). 46 In general, only one or two biochemical indexes were abnormal in the same group of mice, which confirmed the negligible liver and kidney injury of mice by PTX-SLN@CUD. In the cumulative toxicity assay, the relevant indicators of each mouse in the PTX group revealed that there were high values compared to the control group.…”

Section: Blood Biochemical Parametersmentioning

confidence: 60%

Novel Curcumin Derivative-Decorated Ultralong-Circulating Paclitaxel Nanoparticles: A Novel Delivery System with Superior Anticancer Efficacy and Safety

Wei¹,

Zeng²,

Pi³

et al. 2022

IJN

View full text Add to dashboard Cite

Paclitaxel (PTX) has been widely utilized for the treatment of breast cancer. However, drawbacks, such as poor aqueous solubility, rapid blood clearance and severe toxicity, greatly reduce its efficacy and safety. Herein, a novel self-developed curcumin derivative (CUD) was chosen as the carrier to develop a long-acting PTX nano-delivery system (PTX-Sln@CUD) in order to improve its pharmacokinetic behavior, anti-breast cancer efficacy and safety. Methods: PTX-Sln@CUD was prepared using solid dispersion and ultrasonic technology. Relevant physical and chemical properties, including stability and release behavior, were characterized. The clearance of PTX-Sln@CUD in vivo was studied by pharmacokinetic experiments. The anti-tumor activity of PTX-Sln@CUD was investigated in vitro and in vivo. Hemolysis experiments, acute toxicity and cumulative toxicity studies were performed in mice to determine the safety of PTX-Sln@CUD. Results: The average particle size, PDI, Zeta potential, encapsulation efficiency and loading efficiency of the PTX-Sln@CUD were 238.5 ± 4.79 nm, 0.225 ± 0.011, −33.8 ± 1.26 mV, 94.20 ± 0.49% and 10.98 ± 0.31%, respectively. PTX-Sln@CUD was found to be stable at room temperature for half a year. The cumulative release rates of PTX-Sln@CUD at 24, 96 and 168 h were 17.98 ± 2.60, 57.09 ± 2.32 and 72.66 ± 4.16%, respectively, which were adherent to zero-order kinetics. T 1/2 , MRT (0-t) and AUC (0-t) of the PTX-Sln @CUD group were 4. 03-fold (44.293 h), 7.78-fold (38.444 h) and 6.18-fold (14.716 mg/L*h) of the PTX group, respectively. PTX-Sln @CUD group demonstrated stronger anti-breast cancer activity than the PTX group. Importantly, the PTX-Sln@CUD group was safer compared to the PTX group both in vitro and in vivo. Conclusion: PTX-Sln@CUD was verified as promising therapeutic nanoparticles for breast cancer and provided a novel strategy to solve the problem of low efficacy and poor safety of clinical chemotherapy drugs.

show abstract

Section: Blood Biochemical Parametersmentioning

confidence: 60%

Novel Curcumin Derivative-Decorated Ultralong-Circulating Paclitaxel Nanoparticles: A Novel Delivery System with Superior Anticancer Efficacy and Safety

Wei¹,

Zeng²,

Pi³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Blood urea nitrogen (BUN) and serum creatinine (Cr) are two essential indicators widely used in the assessment and evaluation of renal functions independently (Akimoto et al, ; Chen, ; Naqshbandi, Khan, Rizwan, Rehman, & Khan, ). In fact, previous studies have shown that serum Cr and BUN were downregulated in the presence of a corosolic acid or the mutated lactobacilli (Li et al, ; Wang, Jiang, & Liu, ). Recently, many researchers have also noted that serum Cr and BUN levels were markedly increased after some renal‐related treatments, such as the cisplatin treatment, and the renal Ischemia/reperfusion treatment (Domitrovic et al, ; Saigo et al, ).…”

Section: Discussionmentioning

confidence: 96%

WISP1 silencing confers protection against epithelial–mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/β‐catenin signaling pathway in uremia

Chen

Sun

Zheng

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Uremia can affect hepatic metabolism of drugs by regulating the clearance of drugs, but it has not been clarified whether gene silencing could modulate the epithelial–mesenchymal transition (EMT) process in uremia. Hence, we investigated the effect of WISP1 gene silencing on the renal tubular EMT in uremia through the wnt/β‐catenin signaling pathway. Initially, microarray‐based gene expression profiling of uremia was used to identify differentially expressed genes. Following the establishment of uremia rat model, serum creatinine, and urea nitrogen of rats were detected. Renal tubular epithelial cells (TECs) were transfected with shRNA‐WISP1 lentivirus interference vectors and LiCI (the wnt/β‐catenin signaling pathway activator) to explore the regulatory mechanism of WISP1 in uremia in relation to the wnt/β‐catenin signaling pathway. Then, expression of WISP1, wnt2b, E‐cadherin, α‐SMA, c‐myc, Cyclin D1, MMP‐2, and MMP‐9 was determined. Furthermore, TEC migration and invasion were evaluated. Results suggested that WISP1 and the wnt/β‐catenin signaling pathway were associated with uremia. Uremic rats exhibited increased serum creatinine and urea nitrogen levels, upregulated WISPl, and activated wnt/β‐catenin signaling pathway. Subsequently, WISP1 silencing decreased wnt2b, c‐myc, Cyclin D1, α‐SMA, MMP‐2, and MMP‐9 expression but increased E‐cadherin expression, whereas LiCI treatment exhibited the opposite trends. In addition, WISP1 silencing suppressed TEC migration and invasion, whereas LiCI treatment promoted TEC migration and invasion. The findings indicate that WISP1 gene silencing suppresses the activation of the wnt/β‐catenin signaling pathway, thus reducing EMT of renal TECs in uremic rats.

show abstract

“…Comparison of biochemical parameters of mice in the CUD-PTX-LN acute toxicity group with that of the control group, only one mouse had an LDH value slightly below the reference range. In addition, the CREA index of another mouse is slightly lower than the reference range but has no clinical guiding signi cance (Table 2) [41]. In general, only one or two biochemical indexes were abnormal in the same group of mice, con rming to some extent that liver and kidney injury brought by CUD-PTX-LN to mice was limited.…”

Section: Blood Biochemical Parametersmentioning

confidence: 93%

Toxicity, Pharmacokinetics, And Antitumor Activity Study of a Novel Long-Acting Paclitaxel Nanodrug Delivery System Constructed On a Curcumin Derivative Carrier

Zeng

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose/Background: Paclitaxel (PTX) has been widely used in the clinic to treat breast cancer. However, its poor water solubility and intolerable toxicity greatly reduce the efficacy and medication safety. In this paper, a curcumin derivative (CUD) synthesized by the research group was used as a carrier to prepare a new type of PTX nanodrug delivery system (CUD-PTX-LN), thereby improving the safety of PTX medication and enhancing the anti-tumor effect.Methods: CUD-PTX-LN was prepared by solid dispersion technology and the dialysis method was adopted to investigate the release behavior of CUD-PTX-LN in vitro. Meanwhile, the dynamic process of nanoparticles in vivo was analyzed by pharmacokinetic experiments. Hemolysis experiment, acute toxicity and cumulative toxicity were conducted in mice to evaluate the safety of CUD-PTX-LN. Subsequently, the anti-tumor activity of CUD-PTX-LN was investigated using in vitro and in vivo breast cancer cell models.Results: The average particle size, PDI, and Zeta potential of CUD-PTX-LN were 238.5 ± 4.79 nm, 0.225 ± 0.011 and -33.8 ± 1.26 mV, respectively. CUD-PTX-LN had an encapsulation efficiency (%EE) of 94.20 ± 0.49% and an achievable drug loading (%DL) of 10.98 ± 0.31%. This nanoparticle was stable for up to half a year when the lyophilized powder was stored at room temperature. Cytotoxicity test on MCF-7 cells demonstrated the stronger cytotoxic activity of nanoparticles in comparison to free PTX. CUD-PTX-LN significantly prolonged the half-life and retention time of PTX. The area under the curve (AUC) of CUD-PTX-LN was 14.72 mg/L × h, which was 6 times that of the free PTX group (2.38 mg/L × h). In anti-tumor experiments in vivo, CUD-PTX-LN possessed the advantages of improving the antitumor efficacy and reducing the toxic side effects of drugs. Importantly, CUD-PTX-LN is safer than free PTX in terms of assessing hemolytic, acute and cumulative toxicity.Conclusion: A novel PTX nanodrug delivery system constructed based on CUD as a carrier holds great potential in improving breast cancer treatment.

show abstract

The influence of mutant lactobacilli on serum creatinine and urea nitrogen concentrations and renal pathology in 5/6 nephrectomized rats

Cited by 7 publications

References 19 publications

Novel Curcumin Derivative-Decorated Ultralong-Circulating Paclitaxel Nanoparticles: A Novel Delivery System with Superior Anticancer Efficacy and Safety

Novel Curcumin Derivative-Decorated Ultralong-Circulating Paclitaxel Nanoparticles: A Novel Delivery System with Superior Anticancer Efficacy and Safety

WISP1 silencing confers protection against epithelial–mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/β‐catenin signaling pathway in uremia

Toxicity, Pharmacokinetics, And Antitumor Activity Study of a Novel Long-Acting Paclitaxel Nanodrug Delivery System Constructed On a Curcumin Derivative Carrier

Contact Info

Product

Resources

About